Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Eurofins Scientific    ERF   FR0014000MR3

EUROFINS SCIENTIFIC

(ERF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Eurofins : Reports Very Strong Performance With Organic Growth Exceeding 22% in Q3 2020 and Sets New Objectives For 2022

10/22/2020 | 01:21am EST

Today, Eurofins Scientific, a world leader in Testing for Life, employing 50,000 people in 800 laboratories in 50 countries published its Q3 trading statement and on this occasion set new objectives for 2022: https://www.eurofins.com/media-centre/press-releases/2020-10-22/

  • Q3 2020 revenues increased 21.0% year-on-year to EUR 1,413m vs. EUR 1,167m in Q3 2019. Over the first nine months of 2020 (NM 2020), revenues grew 12.0% to EUR 3,736m vs. EUR 3,335m during the same period last year.
  • Organic growth was very strong at +22.7% in Q3 2020 and +11.1% over NM 2020.
  • Despite the continued COVID-19 pandemic related business disruptions, Eurofins core business (excluding any COVID-19 clinical testing and reagents revenues) returned to small positive organic growth in Q3 2020, once again demonstrating the strong resilience of Eurofins’ end markets. Many of Eurofins’ core businesses across Food, Environment and BioPharma testing achieved more than 5% organic growth in Q3 2020.
  • Eurofins continues to demonstrate its strong commitment towards supporting healthcare providers and national and state authorities in their ongoing efforts to mitigate the spread and impact of the virus. As an example of Eurofins’ agility and the strength of its R&D teams, a Eurofins company just received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for their At Home COVID-19 Nasal PCR Test. This is a major milestone in facilitating access to a very sensitive test as sampling by healthcare professionals is often a bottleneck to access gold standard PCR testing. Other developments in the fight against COVID can be found here: https://www.eurofins.com/covid-19-response/
  • Hopefully, the pandemic will be brought under control by 2022. The Group is thus introducing 2022 objectives excluding any COVID-19 testing and clinical reagent revenues: EUR 5.7bn revenue, EUR 1.35bn adjusted EBITDA and EUR 800m Free Cash Flow to the Firm (FCFF), and is optimistic about continued 5% organic growth and margin and FCFF increases beyond this. 2020 and 2021 objectives were unchanged but actual results could be significantly higher, especially in 2020.

About Eurofins – the global leader in bio-analysis

With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.


© Business Wire 2020
All news about EUROFINS SCIENTIFIC
05:45aEurofins Launches New Test, Increased Capacity to Detect SARS-CoV-2 Variants
MT
01:32aEUROFINS : the global leader in analytical testing, expands worldwide face mask ..
BU
01:31aEUROFINS SCIENTIFIC : Launches New Tests and Massive Capacity for Detecting and ..
BU
01/11EUROFINS SCIENTIFIC : Anti-COVID-19 System Gets Emergency Response Validation PT..
MT
01/11EUROFINS SCIENTIFIC : GeneScan Technologies Announces AOAC PTM Accreditation for..
BU
2020EUROFINS SCIENTIFIC : Launches Full-Length COVID-19Viral Genome Sequencing Servi..
MT
2020EUROFINS SCIENTIFIC : Genomics Launches Cost-Effective SARS-CoV-2 full-length Vi..
BU
2020EUROFINS CEREP : Launches PCR COVID-19 Self-Test In Germany, Spain
MT
2020EUROFINS SCIENTIFIC : launches COVID-19 PCR tests with at-home self-sampling opt..
PU
2020EUROFINS SCIENTIFIC : Lifts FY20 Revenue, Profit Outlook On Strong Trading, Orga..
MT
More news
Financials
Sales 2020 5 265 M 6 360 M 6 360 M
Net income 2020 391 M 473 M 473 M
Net Debt 2020 2 866 M 3 462 M 3 462 M
P/E ratio 2020 35,0x
Yield 2020 0,66%
Capitalization 14 262 M 17 243 M 17 228 M
EV / Sales 2020 3,25x
EV / Sales 2021 3,01x
Nbr of Employees 48 000
Free-Float 66,7%
Chart EUROFINS SCIENTIFIC
Duration : Period :
Eurofins Scientific Technical Analysis Chart | ERF | FR0014000MR3 | MarketScreener
Technical analysis trends EUROFINS SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 73,55 €
Last Close Price 75,58 €
Spread / Highest target 12,6%
Spread / Average Target -2,68%
Spread / Lowest Target -49,5%
EPS Revisions
Managers and Directors
NameTitle
Gilles J. Martin Chairman & Chief Executive Officer
Laurent Lebras Director-Group Finance & Administration
Andreas König Chief Information Officer
Yves-Loïc Martin Non-Executive Director
Valérie Hanote Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
EUROFINS SCIENTIFIC10.13%17 515
SQUARE, INC.6.96%104 974
FISERV, INC.-5.16%72 394
GLOBAL PAYMENTS INC.-9.94%58 071
CINTAS CORPORATION-7.45%34 360
OFFCN EDUCATION TECHNOLOGY CO., LTD.-5.21%32 531